Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The Lithuanian Ambassador to the United Kingdom, His Excellency Mr Eitvydas Bajarūnas, paid a visit to Professor Skirmantas Kriaučionis of the Ludwig Institute for Cancer Research at the Nuffield Department of Medicine.

Eitvydas Bajarūnas, the Lithuanian Ambassador to the United Kingdom, and First Secretaries Gitana Šukaitytė and Tadas Kubilius visited Nuffield Department of Medicine’s Ludwig Oxford branch last week and met with group leader Prof Skirmantas Kriaučionis to discuss his work on DNA modifications in cancer.

Prof Skirmantas, whose interest in scientific research began in his native Lithuania, received a prestigious award from the Lithuanian Ministry of Education and Science following his discovery of the modified DNA base, 5-hydroxymethylcytosine. This award is given to prominent Lithuanian scientists working abroad in physics, biomedical sciences and technology, and encourages collaborative links with scientific and academic communities in Lithuania.

Following the meeting, Prof Skirmantas said: “This was an exciting opportunity to discuss avenues for future interaction, including incentives for talented Lithuanian students to come to study in Oxford and ways to facilitate collaborations between life science academics in the UK and Lithuania. Based on our respective experiences in different countries, we discussed success stories in Sweden and the US, such as promoting a culture of entrepreneurship in different sectors and nurturing philanthropies for science funding.”

Commenting on the visit, Ambassador Bajarūnas said: “It is a great pleasure to hear about the important work being carried out by the Ludwig Institute at the University of Oxford by Skirmantas and his colleagues. Future challenges in cancer research will undoubtedly require international collaborations, and we will continue to give our full support to partnerships between the UK and Lithuanian life sciences communities.”

You can learn more about work in the Kriaučionis lab here.

Similar stories

Côte d’Ivoire becomes first nation to deploy R21 malaria vaccine

Côte d’Ivoire will become the first country to roll-out the new R21/Matrix-M™ vaccine with the first child vaccinated in Abidjan, marking a critical step and historic milestone in the global fight against malaria. 15 African countries are expected to introduce malaria vaccines with Gavi support in 2024, and countries plan to reach around 6.6 million children with the malaria vaccine in 2024 and 2025. The new vaccine has been authorised by Ghana, Nigeria, Burkina Faso and the Central African Republic, and many others are preparing to receive shipments.